Sign up Australia
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: AcelRX Pharmaceuticals shares sink after public offering announcement

The biotech is offering more than 7 million shares, expecting to raise as much as US$20mln
Small-Cap Snapshot: AcelRX Pharmaceuticals shares sink after public offering announcement
Shares of its common stock have been priced at US$2.75 per share

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is a top decliner after announcing pricing of a public offering of common stock. The biotech is offering more than 7 million shares at a price of US$2.75 per share. The offering is expected to raise US$20mln to be used for general corporate purposes, including the funding of early commercialization efforts. The specialty pharma company develops under-the-tongue therapies for acute pain. Shares of the California-based company were down nearly 13% to US$2.97 in Thursday morning trading.

Zogenix Inc (NASDAQ:ZGNX) shares jumped following positive results from its late-stage trial of its epilepsy drug. The Phase 3 trial showed that its drug ZX008 was able to reduce the frequency of convulsive seizures. The drug is designed to treat children and young adults with Dravet syndrome. Shares of the California-based biotech were up more than 15% to US$53.42.

READ: Zogenix shares pop on impressive Phase 3 results for epilepsy drug

Engility Holdings Inc (NYSE:EGL) shares are up after reports that the government contractor is exploring a sale. The US defense contractor is said to have attracted companies like CACI International Inc and Science Applications International Corp, according to a Reuters report. The company provides engineering and logistics services to US military and civilian agencies. Shares of the company jumped more than 13% to US$35.79.

The Cato Corporation (NYSE:CATO) is another top decliner following disappointing sales in June. The apparel company reported below-expectation same-store sales. Sales decreased by 2% to US$72.9mln compared with sales of US$74.7mln last June. The company operates 1,350 stores in 33 states, 24 fewer stores than last year. Shares of the North Carolina-based company were down more than 13% to US$21.56.

The Russell 2000 Small-Cap Index saw minimal gains in Thursday morning trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full ACRX profile View Profile

AcelRx Pharmaceuticals Timeline

Related Articles

pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
1521490126_shutterstock_234586750.jpg
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use